99 related articles for article (PubMed ID: 26806308)
21. Clinical significance of microRNA-155 expression in human breast cancer.
Chen J; Wang BC; Tang JH
J Surg Oncol; 2012 Sep; 106(3):260-6. PubMed ID: 22105810
[TBL] [Abstract][Full Text] [Related]
22. TGF-β1 induces HMGA1 expression in human breast cancer cells: implications of the involvement of HMGA1 in TGF-β signaling.
Zu X; Zhong J; Tan J; Tan L; Yang D; Zhang Q; Ding W; Liu W; Wen G; Liu J; Cao R; Jiang Y
Int J Mol Med; 2015 Mar; 35(3):693-701. PubMed ID: 25572132
[TBL] [Abstract][Full Text] [Related]
23. miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2.
Fu J; Xu X; Kang L; Zhou L; Wang S; Lu J; Cheng L; Fan Z; Yuan B; Tian P; Zheng X; Yu C; Ye Q; Lv Z
Biochem Biophys Res Commun; 2014 Mar; 445(2):314-9. PubMed ID: 24508260
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-10a is reduced in breast cancer and regulated in part through retinoic acid.
Khan S; Wall D; Curran C; Newell J; Kerin MJ; Dwyer RM
BMC Cancer; 2015 May; 15():345. PubMed ID: 25934412
[TBL] [Abstract][Full Text] [Related]
25. Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer.
Yoshimoto N; Toyama T; Takahashi S; Sugiura H; Endo Y; Iwasa M; Fujii Y; Yamashita H
Breast Cancer Res Treat; 2011 Nov; 130(1):331-9. PubMed ID: 21755340
[TBL] [Abstract][Full Text] [Related]
26. Expression of miR‑26a exhibits a negative correlation with HMGA1 and regulates cancer progression by targeting HMGA1 in lung adenocarcinoma cells.
Sekimoto N; Suzuki A; Suzuki Y; Sugano S
Mol Med Rep; 2017 Feb; 15(2):534-542. PubMed ID: 28000891
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of HMGA1 correlates with the malignant status and prognosis of breast cancer.
Huang R; Huang D; Dai W; Yang F
Mol Cell Biochem; 2015 Jun; 404(1-2):251-7. PubMed ID: 25772486
[TBL] [Abstract][Full Text] [Related]
28. Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells.
Treff NR; Dement GA; Adair JE; Britt RL; Nie R; Shima JE; Taylor WE; Reeves R
Oncogene; 2004 Nov; 23(52):8557-62. PubMed ID: 15378028
[TBL] [Abstract][Full Text] [Related]
29. An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples.
Xiong J; Yu D; Wei N; Fu H; Cai T; Huang Y; Wu C; Zheng X; Du Q; Lin D; Liang Z
FEBS J; 2010 Apr; 277(7):1684-94. PubMed ID: 20180843
[TBL] [Abstract][Full Text] [Related]
30. High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer.
Gorbounov M; Carleton NM; Asch-Kendrick RJ; Xian L; Rooper L; Chia L; Cimino-Mathews A; Cope L; Meeker A; Stearns V; Veltri RW; Bae YK; Resar LMS
Breast Cancer Res Treat; 2020 Jan; 179(1):25-35. PubMed ID: 31531802
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer.
Endo Y; Yamashita H; Takahashi S; Sato S; Yoshimoto N; Asano T; Hato Y; Dong Y; Fujii Y; Toyama T
BMC Cancer; 2014 Dec; 14():990. PubMed ID: 25528056
[TBL] [Abstract][Full Text] [Related]
32. MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer.
Christensen LL; Tobiasen H; Holm A; Schepeler T; Ostenfeld MS; Thorsen K; Rasmussen MH; Birkenkamp-Demtroeder K; Sieber OM; Gibbs P; Lubinski J; Lamy P; ; Laurberg S; Oster B; Hansen KQ; Hagemann-Madsen R; Byskov K; Ørntoft TF; Andersen CL
Int J Cancer; 2013 Jul; 133(1):67-78. PubMed ID: 23280316
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
[TBL] [Abstract][Full Text] [Related]
34. COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation.
Majumder M; Landman E; Liu L; Hess D; Lala PK
Mol Cancer Res; 2015 Jun; 13(6):1022-33. PubMed ID: 25733698
[TBL] [Abstract][Full Text] [Related]
35. miR-494 suppresses the progression of breast cancer in vitro by targeting CXCR4 through the Wnt/β-catenin signaling pathway.
Song L; Liu D; Wang B; He J; Zhang S; Dai Z; Ma X; Wang X
Oncol Rep; 2015 Jul; 34(1):525-31. PubMed ID: 25955111
[TBL] [Abstract][Full Text] [Related]
36. miR-96 promotes tumor proliferation and invasion by targeting RECK in breast cancer.
Zhang J; Kong X; Li J; Luo Q; Li X; Shen L; Chen L; Fang L
Oncol Rep; 2014 Mar; 31(3):1357-63. PubMed ID: 24366472
[TBL] [Abstract][Full Text] [Related]
37. Diminished expression of MiR-15a is an independent prognostic marker for breast cancer cases.
Shinden Y; Akiyoshi S; Ueo H; Nambara S; Saito T; Komatsu H; Ueda M; Hirata H; Sakimura S; Uchi R; Takano Y; Iguchi T; Eguchi H; Sugimachi K; Kijima Y; Ueo H; Natsugoe S; Mimori K
Anticancer Res; 2015 Jan; 35(1):123-7. PubMed ID: 25550542
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance.
Huynh FC; Jones FE
PLoS One; 2014; 9(12):e114419. PubMed ID: 25532106
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer.
Nagpal N; Ahmad HM; Molparia B; Kulshreshtha R
Carcinogenesis; 2013 Aug; 34(8):1889-99. PubMed ID: 23542418
[TBL] [Abstract][Full Text] [Related]
40. MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer.
Luo Q; Li X; Li J; Kong X; Zhang J; Chen L; Huang Y; Fang L
Int J Oncol; 2013 Oct; 43(4):1212-8. PubMed ID: 23900351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
